Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition*
References (36)
- et al.
Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach
J Biol Chem
(1996) - et al.
Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells
J Biol Chem
(1993) - et al.
Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats
Biochem Biophys Res Commun
(2001) - et al.
Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
Eur J Pharmacol
(2000) - et al.
Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide
Metabolism
(1999) - et al.
Incretin hormone expression in the gut of diabetic mice and rats
Metabolism
(1997) - et al.
Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas
Res Exp Med
(1993) Enteroglucagon
Annu Rev Physiol
(1997)Glucagon-like peptides
Diabetes
(1998)The entero-insular axis in type 2 diabetes—Incretins as therapeutic agents
Exp Clin Endocrinol Diabetes
(2001)
Effect of aging and diabetes on the enteroinsular axis
J Gerontol
Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes
Curr Pharm Des
Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells
Endocrinology
Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats
Endocrinology
Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus
N Engl J Med
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
Diabetologia
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
J Clin Invest
Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM
Diabetes Care
Cited by (51)
Gemigliptin suppresses salivary dysfunction in streptozotocin-induced diabetic rats
2021, Biomedicine and PharmacotherapyCitation Excerpt :In previous reports, similar inefficacy of DPP-4 inhibitors on blood glucose levels has been observed in diabetic animal models [31–33]. Nagakura et al. have reported that DPP-4 inhibitors were unable to improve hyperglycemia in animal models presenting late-stage diabetes [34]. Several recent studies have revealed that individual DPP4 inhibitors demonstrate protective effects against some diabetic complications via distinct off-target actions.
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
2016, Metabolism: Clinical and ExperimentalImportant species differences regarding lymph contribution to gut hormone responses
2015, PeptidesCitation Excerpt :Intact GLP-1 levels were measured using an in-house 2-site sandwich ELISA for GLP-1 as described previously [18]. DPP-4 activity was assessed kinetically by standard procedures, using H-Gly-Pro-p-nitroaniline as substrate [16], with minor modifications. Total GLP-1 and intact GLP-1 responses were evaluated by AUC (total AUC: whole experiment, incremental AUC: stimulation period with NC) calculated using the trapezoidal rule, tested by paired t-test, and two-way ANOVA for repeated measurement followed by Bonferroni post hoc analysis as appropriate.
Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy
2015, European Journal of Pharmacology
- *
Address reprint requests to Kazuto Yamazaki, PhD, Tsukuba Research Laboratories, Eisai Co, Ltd, 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan.